429 related articles for article (PubMed ID: 32574517)
41. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry.
Gao J; Kalafatis D; Carlson L; Pesonen IHA; Li CX; Wheelock Å; Magnusson JM; Sköld CM
Respir Res; 2021 Feb; 22(1):40. PubMed ID: 33546682
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic and treatment standards in idiopathic pulmonary fibrosis in the era of antifibrotic drugs in Poland: A real-world practice survey.
Majewski S; Lewandowska K; Martusewicz-Boros MM; Piotrowski WJ
Adv Respir Med; 2019; 87(6):221-230. PubMed ID: 31970724
[TBL] [Abstract][Full Text] [Related]
43. Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry.
Summer R; Todd JL; Neely ML; Lobo LJ; Namen A; Newby LK; Shafazand S; Suliman S; Hesslinger C; Keller S; Leonard TB; Palmer SM; Ilkayeva O; Muehlbauer MJ; Newgard CB; Roman J
Respir Res; 2024 Jan; 25(1):58. PubMed ID: 38273290
[TBL] [Abstract][Full Text] [Related]
44. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
[TBL] [Abstract][Full Text] [Related]
45. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry.
Todd JL; Neely ML; Overton R; Durham K; Gulati M; Huang H; Roman J; Newby LK; Flaherty KR; Vinisko R; Liu Y; Roy J; Schmid R; Strobel B; Hesslinger C; Leonard TB; Noth I; Belperio JA; Palmer SM;
Respir Res; 2019 Oct; 20(1):227. PubMed ID: 31640794
[TBL] [Abstract][Full Text] [Related]
46. Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis.
Kaul B; Lee JS; Petersen LA; McCulloch C; Rosas IO; Bandi VD; Zhang N; DeDent AM; Collard HR; Whooley MA
Chest; 2023 Aug; 164(2):441-449. PubMed ID: 36801465
[TBL] [Abstract][Full Text] [Related]
47. Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry.
de Andrade JA; Kulkarni T; Neely ML; Hellkamp AS; Case AH; Guntupalli K; Bender S; Conoscenti CS; Snyder LD;
Respir Med; 2021; 189():106637. PubMed ID: 34656903
[TBL] [Abstract][Full Text] [Related]
48. Effects of Qizhukangxian granules on idiopathic pulmonary fibrosis: a randomized, double blind, placebo-controlled and multicenter clinical pilot trial.
Guo S; Song Y; Feng J; Liu S; Li Y; Liu M; Wei L; Zhang X; Xie H; Sun Z
J Tradit Chin Med; 2020 Aug; 40(4):674-682. PubMed ID: 32744035
[TBL] [Abstract][Full Text] [Related]
49. A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis.
Harari S; Caminati A; Poletti V; Confalonieri M; Gasparini S; Lacedonia D; Luppi F; Pesci A; Sebastiani A; Spagnolo P; Vancheri C; Balestro E; Bonifazi M; Cerri S; De Giacomi F; Della Porta R; Foschino Barbaro MP; Fui A; Pasquinelli P; Rosso R; Tomassetti S; Specchia C; Rottoli P;
Respiration; 2018; 95(6):433-440. PubMed ID: 29587263
[TBL] [Abstract][Full Text] [Related]
50. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
51. Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries.
Pesonen I; Carlson L; Murgia N; Kaarteenaho R; Sköld CM; Myllärniemi M; Ferrara G
Multidiscip Respir Med; 2018; 13():14. PubMed ID: 29785264
[TBL] [Abstract][Full Text] [Related]
52. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
53. Investigation of clinical predictors of survival in idiopathic pulmonary fibrosis patients: A cohort study in Taiwan.
Tseng CM; Chen MY; Kao CY; Tao CW
J Chin Med Assoc; 2022 May; 85(5):578-583. PubMed ID: 35353790
[TBL] [Abstract][Full Text] [Related]
54. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
[TBL] [Abstract][Full Text] [Related]
55. National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care.
Salonen J; Purokivi M; Hodgson U; Kaarteenaho R
BMJ Open Respir Res; 2022 Sep; 9(1):. PubMed ID: 36571594
[TBL] [Abstract][Full Text] [Related]
56. Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis.
Wright WA; Crowley LE; Parekh D; Crawshaw A; Dosanjh DP; Nightingale P; Thickett DR
BMJ Open Respir Res; 2021 Mar; 8(1):. PubMed ID: 33771813
[TBL] [Abstract][Full Text] [Related]
57. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
[TBL] [Abstract][Full Text] [Related]
58. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
Maher TM; Strek ME
Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
[TBL] [Abstract][Full Text] [Related]
59. Overall drug treatment of idiopathic pulmonary fibrosis patients from national registries - a real-world study from Finland.
Kaunisto J; Salomaa ER; Koivisto M; Myllärniemi M
BMC Pulm Med; 2023 Sep; 23(1):364. PubMed ID: 37777734
[TBL] [Abstract][Full Text] [Related]
60. Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry.
Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Rizzo S; Kirchgaessler KU; Bartley K; Bondue B
Pulm Ther; 2022 Jun; 8(2):181-194. PubMed ID: 35429319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
